Reported 1 day ago
Kepler Capital has reaffirmed its Buy rating for Novo Nordisk A/S (NVO), setting a price target of DKK 630. The company reported a 22% increase in operating profit and significant growth in both US and International Operations, particularly in diabetes and obesity care, indicating robust performance in the healthcare sector.
Source: YAHOO